CDKN2A/B Deletions Are Associated With Inferior Outcomes With First-Line Immune Checkpoint Inhibitor-Based Therapy in Advanced Non-small Cell Lung Carcinoma
CDKN2A/B Deletions Are Associated With Inferior Outcomes With First-Line Immune Checkpoint Inhibitor-Based Therapy in Advanced Non-small Cell Lung Carcinoma. // JTO Clinical and Research Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2666364326001517?dgcid=rss_sd_all
CDKN2A/B Deletions Are Associated With Inferior Outcomes With First-Line Immune Checkpoint Inhibitor-Based Therapy in Advanced Non-small Cell Lung Carcinoma. JTO Clinical and Research Reports. https://www.sciencedirect.com/science/article/pii/S2666364326001517?dgcid=rss_sd_all
“CDKN2A/B Deletions Are Associated With Inferior Outcomes With First-Line Immune Checkpoint Inhibitor-Based Therapy in Advanced Non-small Cell Lung Carcinoma.” JTO Clinical and Research Reports.
@article{article94612,
title = {CDKN2A/B Deletions Are Associated With Inferior Outcomes With First-Line Immune Checkpoint Inhibitor-Based Therapy in Advanced Non-small Cell Lung Carcinoma},
journal = {JTO Clinical and Research Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2666364326001517?dgcid=rss_sd_all}
}